Sort by
Refine Your Search
-
Listed
-
Employer
- Cranfield University
- ; Swansea University
- ;
- ; University of Surrey
- University of Nottingham
- ; Newcastle University
- ; University of Nottingham
- ; University of Southampton
- ; The University of Manchester
- ; University of Birmingham
- Abertay University
- ; Brunel University London
- ; Cranfield University
- ; King's College London
- ; Manchester Metropolitan University
- ; University of East Anglia
- ; University of Exeter
- ; University of Oxford
- ; University of Plymouth
- ; University of Sussex
- ; University of Warwick
- King's College London;
- Swansea University
- The University of Manchester
- The University of Manchester;
- University of Bristol
- University of Cambridge
- University of Manchester
- University of Plymouth
- University of Warwick
- 20 more »
- « less
-
Field
-
Supervisors: Dr Tim Halim and Dr Gregory Hamm Course start: 1st October 2026 Overview The project will be supervised by Dr Tim Halim, Dr Albert Koulman (Institute of Metabolic Science) and Dr Gregory Hamm (AstraZeneca). Project details The tumour immunity cycle involves cyclical trafficking of...
-
resistance and a profoundly immunosuppressive tumour microenvironment (TME). There is a critical need for novel therapeutic strategies that target both tumour-intrinsic mechanisms and immune evasion. Our
-
approach utilises the inherent need of the tumour for extracellular arginine and to use this to deliver a toxic moiety to the tumour; in other words, we will use the arginine structural motif as a targeting
-
the gut-brain and gut-muscle axes, as potentially key modulators of cognitive function, and physical health in middle-aged-to-older adults. The central theme will be to investigate how targeted
-
PhD Studentship: Dissecting the Molecular Architecture and Function of LMTK3 as a Therapeutic Target
; University of Sussex | The City of Brighton and Hove, England | United Kingdom | about 1 month agoLemur Taul Kinase 3 (LMTK3) has emerged as a significant therapeutic target in a range of cancers, most notably breast cancer. Previous research from the laboratory of Professor Georgios Giamas
-
Paediatric services, including KCH), and age- and gender-matched healthy controls. Parts 2 and 3 are under development. Part 2 will involve a targeted neuroimaging (EEG and/or fMRI) intervention study with a
-
will be grounded in rigorous mathematics coupled with a sound understanding of the underlying earthworm ecology. Bayesian inference methodologies will be developed to estimate where and when behavioural
-
are suitable. The aims of this project are to Review operating characteristics proposed for rare disease trials Develop novel Bayesian operating characteristics for different types of rare disease trials Apply
-
for health policy decision-making, these methods will be developed using a Bayesian framework. This PhD project will deliver a substantial contribution to original research in the area of health data science
-
limited. No immunotherapy for meningiomas has yet gained FDA approval, though early-phase trials targeting IFN-alpha and PD-1 have been conducted. Emerging evidence highlights the crucial role of the immune